SVB Leerink cut shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) from an outperform rating to a market perform rating in a research note published on Friday morning, Marketbeat reports. SVB Leerink currently has $3.00 target price on the stock, down from their previous target price of $5.00.
Other equities research analysts also recently issued reports about the company. Oppenheimer decreased their price objective on Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. Royal Bank of Canada cut their target price on Viracta Therapeutics from $6.00 to $4.00 and set an outperform rating on the stock in a research report on Thursday, August 15th.
View Our Latest Stock Report on VIRX
Viracta Therapeutics Price Performance
About Viracta Therapeutics
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Featured Stories
- Five stocks we like better than Viracta Therapeutics
- 3 Small Caps With Big Return Potential
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is a Secondary Public Offering? What Investors Need to Know
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Healthcare Dividend Stocks to Buy
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.